Literature DB >> 18096573

Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils.

Bogdan Iorga1, Natascha Blaudeck, Johannes Solzin, Axel Neulen, Ina Stehle, Alfredo J Lopez Davila, Gabriele Pfitzer, Robert Stehle.   

Abstract

AIMS: To understand the functional consequences of the Lys184 deletion in murine cardiac troponin I (mcTnI(DeltaK184)), we have studied the primary effects of this mutation linked to familial hypertrophic cardiomyopathy (FHC) at the sarcomeric level. METHODS AND
RESULTS: Ca(2+) sensitivity and kinetics of force development and relaxation were investigated in cardiac myofibrils from transgenic mice expressing mcTnI(DeltaK184), as a model which co-segregates with FHC. Ca(2+)-dependent conformational changes (switch-on/off) of the fluorescence-labelled human troponin complex, containing either wild-type hcTnI or mutant hcTnI(DeltaK183), were investigated in myofibrils prepared from the guinea pig left ventricle. Ca(2+) sensitivity and maximum Ca(2+)-activated and passive forces were significantly enhanced and cooperativity was reduced in mutant myofibrils. At partial Ca(2+) activation, mutant but not wild-type myofibrils displayed spontaneous oscillatory contraction of sarcomeres. Both conformational switch-off rates of the incorporated troponin complex and the myofibrillar relaxation kinetics were slowed down by the mutation. Impaired relaxation kinetics and increased force at low [Ca(2+)] were reversed by 2,3-butanedione monoxime (BDM), which traps cross-bridges in non-force-generating states.
CONCLUSION: We conclude that these changes are not due to alterations of the intrinsic cross-bridge kinetics. The molecular mechanism of sarcomeric diastolic dysfunction in this FHC model is based on the impaired regulatory switch-off kinetics of cTnI, which induces incomplete inhibition of force-generating cross-bridges at low [Ca(2+)] and thereby slows down relaxation of sarcomeres. Ca(2+) sensitization and impairment of the relaxation of sarcomeres induced by this mutation may underlie the enhanced systolic function and diastolic dysfunction at the sarcomeric level.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096573     DOI: 10.1093/cvr/cvm113

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  19 in total

1.  Arginylation regulates myofibrils to maintain heart function and prevent dilated cardiomyopathy.

Authors:  Satoshi Kurosaka; N Adrian Leu; Ivan Pavlov; Xuemei Han; Paula Aver Bretanha Ribeiro; Tao Xu; Ralph Bunte; Sougata Saha; Junling Wang; Anabelle Cornachione; Wilfried Mai; John R Yates; Dilson E Rassier; Anna Kashina
Journal:  J Mol Cell Cardiol       Date:  2012-05-21       Impact factor: 5.000

2.  Deletion of the titin N2B region accelerates myofibrillar force development but does not alter relaxation kinetics.

Authors:  Fatiha Elhamine; Michael H Radke; Gabriele Pfitzer; Henk Granzier; Michael Gotthardt; Robert Stehle
Journal:  J Cell Sci       Date:  2014-06-30       Impact factor: 5.285

3.  Pathogenic peptide deviations support a model of adaptive evolution of chordate cardiac performance by troponin mutations.

Authors:  Nathan J Palpant; Evelyne M Houang; Wayne Delport; Kenneth E M Hastings; Alexey V Onufriev; Yuk Y Sham; Joseph M Metzger
Journal:  Physiol Genomics       Date:  2010-04-27       Impact factor: 3.107

4.  Engineered troponin C constructs correct disease-related cardiac myofilament calcium sensitivity.

Authors:  Bin Liu; Ryan S Lee; Brandon J Biesiadecki; Svetlana B Tikunova; Jonathan P Davis
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

5.  The curious role of sarcomeric proteins in control of diverse processes in cardiac myocytes.

Authors:  R John Solaro; Katherine A Sheehan; Ming Lei; Yunbo Ke
Journal:  J Gen Physiol       Date:  2010-07       Impact factor: 4.086

Review 6.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

7.  Mechanical and energetic properties of papillary muscle from ACTC E99K transgenic mouse models of hypertrophic cardiomyopathy.

Authors:  Weihua Song; Petr G Vikhorev; Mavin N Kashyap; Christina Rowlands; Michael A Ferenczi; Roger C Woledge; Kenneth MacLeod; Steven Marston; Nancy A Curtin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

Review 8.  TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships.

Authors:  Juan-Juan Sheng; Jian-Ping Jin
Journal:  Gene       Date:  2015-10-23       Impact factor: 3.688

9.  Insights into the kinetics of Ca2+-regulated contraction and relaxation from myofibril studies.

Authors:  Robert Stehle; Johannes Solzin; Bogdan Iorga; Corrado Poggesi
Journal:  Pflugers Arch       Date:  2009-01-23       Impact factor: 3.657

10.  Strong cross-bridges potentiate the Ca(2+) affinity changes produced by hypertrophic cardiomyopathy cardiac troponin C mutants in myofilaments: a fast kinetic approach.

Authors:  Jose Renato Pinto; Daniel P Reynaldo; Michelle S Parvatiyar; David Dweck; Jingsheng Liang; Michelle A Jones; Martha M Sorenson; James D Potter
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.